Erik Skaaheim Haug

Prof. Dr. Erik Skaaheim Haug

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KCKarolina Cyll
Karolina Cyll
AKAndreas Kleppe
Andreas Kleppe
JKJoakim Kalsnes
Joakim Kalsnes
LVLjiljana Vlatkovic
Ljiljana Vlatkovic
MPManohar Pradhan
Manohar Pradhan
HDHåvard Danielsen
Håvard Danielsen
Machine learning (ML) is expected to improve biomarker assessment. Using convolution neural networks, we developed a fully-automated method for assessing PTEN protein status in immunohistochemically-stained slides using a radical prostatectomy (RP) cohort (n = 253). It was validated according to a predefined protocol in an independent RP cohort (n = 259), alone and by measuring its prognostic value in combination with DNA ploidy status determined by ML-based image cytometry. In the primary analysis, automatically assessed dichotomized PTEN status was associated with time to biochemical recurrence (TTBCR) (hazard ratio (HR) = 3.32, 95% CI 2.05 to 5.38). Patients with both non-diploid tumors and PTEN-low had an HR of 4.63 (95% CI 2.50 to 8.57), while patients with one of these characteristics had an HR of 1.94 (95% CI 1.15 to 3.30), compared to patients with diploid tumors and PTEN-high, in univariable analysis of TTBCR in the validation cohort. Automatic PTEN scoring was strongly predictive of the PTEN status assessed by human experts (area under the curve 0.987 (95% CI 0.968 to 0.994)). This suggests that PTEN status can be accurately assessed using ML, and that the combined marker of automatically assessed PTEN and DNA ploidy status may provide an objective supplement to the existing risk stratification factors in prostate cancer.

25 April 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KCKarolina Cyll
Karolina Cyll
SLSven Löffeler
Sven Löffeler
BCBirgitte Carlsen
Birgitte Carlsen
KSKarin Skogstad
Karin Skogstad
MPMay Lisbeth Plathan
May Lisbeth Plathan
EHErik Skaaheim Haug
Erik Skaaheim Haug
Active surveillance (AS) is standard of care for patients with low-risk prostate cancer (PCa), but its feasibility in intermediate-risk patients is controversial. We compared outcomes of low- and intermediate-risk patients managed with multiparametric magnetic resonance imaging (mpMRI)-supported AS in a community hospital. Of the 433 patients enrolled in AS between 2009 and 2016, 358 complied with AS inclusion criteria (Cancer of the Prostate Risk Assessment (CAPRA) score ≤ 5, Gleason grade group (GGG) ≤ 2, clinical stage ≤ cT2 and prostate-specific antigen (PSA) ≤ 20 ng/ml) and discontinuation criteria (histological-, PSA-, clinical- or radiological disease reclassification). Of the 358 patients, 177 (49%) were low-risk and 181 (51%) were intermediate-risk. Median follow-up was 4.2 years. The estimated 5-year treatment-free survival (TFS) was 56% (95% confidence interval [CI] 51–62%). Intermediate-risk patients had significantly shorter TFS compared with low-risk patients (hazard ratio 2.01, 95% CI 1.47–2.76, p < 0.001). There were no statistically significant differences in the rate of adverse pathology, biochemical recurrence-free survival and overall survival between low- and intermediate-risk patients. Two patients developed metastatic disease and three died of PCa. These results suggest that selected patients with intermediate-risk PCa may be safely managed by mpMRI-supported AS, but longer follow-up is necessary.

2 July 2025 in Quality of Life Research
Verified
Journal Article
Open access
YGY. M. Gjelsvik
Y. M. Gjelsvik
TMT. Å. Myklebust
T. Å. Myklebust
SFS. D. Fosså
S. D. Fosså
EHErik Skaaheim Haug
Erik Skaaheim Haug
RKR. Kvåle
R. Kvåle
TJT. B. Johannesen
T. B. Johannesen
Purpose: Patient-reported outcomes (PROs) provide valuable information on adverse effects of cancer treatment. The aim of this study was to describe the feasibility of a population-based PROs collection and identify factors affecting participation. Methods: A total of 13 595 patients diagnosed with prostate cancer (PCa) 2017–2019, along with 10 653 age- and region-matched men with no history of PCa (controls), were invited to a health survey collecting PROs shortly after diagnosis and again one and three years after the initial invitation. Invitations were sent by digital or regular mail. The survey included Norwegian translations of the EQ-5D-5L, EORTC QLQ-C30, and EPIC-26 instruments. We assessed participation rates in all three survey rounds. Results: We invited 90% of newly diagnosed PCa patients to round 1 of the survey. Participation was higher among patients (58%) than controls (34%), with the highest response rate among digitally invited patients aged 60–69 (66%). Among patients, 44% participated in both rounds 1 and 2. Almost one third (32%) of the invited patients participated in all three rounds. Factors associated with higher participation included digital invitation, higher education, lower age, and being treated with curative intent. Among participants treated with curative intent, 51% completed the first questionnaire before starting local treatment. Conclusions: National registry-based PROs data collection is feasible for both PCa patients and controls. However, both non-responder and attrition biases are likely to influence questionnaire results. Institutions conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data. Plain English summary: The Cancer Registry of Norway invited all Norwegian prostate cancer patients diagnosed between 2017 and 2019 to participate in a three-year health and quality of life survey. This study examines the success of the set-up of this nationwide survey. Patients received the first questionnaire at least six weeks after diagnosis, followed by the second and third questionnaires one and three years later. A control group consisting of men with no history of prostate cancer was also invited. We sent invitations as digital or regular (paper) mail. We used widely recognised questionnaires to assess health and quality of life in prostate cancer patients. Of the 13 595 patients invited, 58% participated in the first round. Among the 10 653 controls invited, 34% participated. The combined participation rate for patients in the first two rounds was 44%, and 32% for all three rounds. We found that digital invitation, higher education, lower age, and curative treatment were associated with higher response rates. We have shown that it is possible to conduct a registry-based national health survey over time among patients and controls. However, questionnaire results may not be representative due to non-responders and responders being different regarding, e.g., education, age and treatment. Therefore, those conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data.

28 March 2017 in Tidsskrift for Den norske legeforening
Verified
Journal Article
Open access
EHErik Skaaheim Haug
Erik Skaaheim Haug
Leder - I sykehus med et høyt antall kirurgiske prosedyrer kan man sannsynligvis oppnå bedre resultater.

25 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EKEirik Kjøbli Eirik Kjøbli
Eirik Kjøbli Eirik Kjøbli
EHErik Skaaheim Haug
Erik Skaaheim Haug
ØSØyvind Salvesen
Øyvind Salvesen
CAChristian Arstad
Christian Arstad
ABAnne Kvaale Bergesen
Anne Kvaale Bergesen
CBChristian Beisland
Christian Beisland
Background: Pelvic lymph node dissection during standard radical cystectomy (stdRC) for muscle invasive bladder cancer is performed as separate templates. In the modernized en bloc radical cystectomy (mEbRC), the bladder is removed together with all its associated lymphatic tissue as one specimen. Our aim was to evaluate the oncological and surgical outcomes of mEbRC with a propensity-matched national cohort of stdRC cases. Methods: 935 patients (mEbRC: 214 and stdRC: 721) were eligible for analysis, and 1:2 propensity score matching was performed regressing mEbRC treatment on the variables age, gender, neoadjuvant chemotherapy, Charlson Comorbidity Index, lymph node metastases at final pathology, carcinoma in situ, and pT-stage. The primary outcome was recurrence-free survival (RFS). Secondary endpoints were overall survival (OS) and cancer-specific survival (CSS), survival for female patients. and perioperative measures. Results: There were no significant differences between the groups regarding complications, 30-day readmission rates, and 30- and 90-day mortality rates. In the propensity score matched groups, the 5-year RFS was 83% in the mEbRC group vs. 67% in the stdRC group (p < 0.001), the CSS was 89% and 78% (p ≤ 0.001), and OS 81% vs. 68% (p < 0.001) in the same groups, respectively. The results were confirmed by Cox regression analyses with hazard ratios ranging from 0.41 to 0.50 and p-values ≤ 0.001, favoring mEbRC. The 5-year OS for female patients was 86% for mEbRC and 60% for stdRC (p = 0.022). Conclusions: Performing mEbRC over stdRC might yield significantly better oncological outcomes, with equal survival rates for both genders.

4 March 2022 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
EHErik Skaaheim Haug
Erik Skaaheim Haug
The medical record has during ages served as the main documentation of medical practice and is still mandatory for practicing doctors in most countries. From handwritten notes in a protocol kept by...